Navigation Links
Neurocrine Biosciences Reports Third Quarter 2009 Results
Date:10/28/2009

ollaborators for development, commercial manufacturing and marketing and sales activities. In addition, the Company faces risks and uncertainties with respect to the Company's R & D pipeline including risk that the Company's urocortin 2, and VMAT2 clinical candidates will not proceed to later stage clinical trials, and risk that the Company's research programs will not identify pre-clinical candidates for further development. With respect to its pipeline overall, the Company faces risk that it will be unable to raise additional funding required to complete development of all of its product candidates; risk relating to the Company's dependence on contract manufacturers for clinical drug supply; risks associated with the Company's dependence on corporate collaborators for commercial manufacturing and marketing and sales activities; uncertainties relating to patent protection and intellectual property rights of third parties; risks and uncertainties relating to competitive products and technological changes that may limit demand for the Company's products; and the other risks described in the Company's report on Form 10-K for the year ended December 31, 2008 and Form 10-Q for the quarter ended June 30, 2009. Neurocrine undertakes no obligation to update the statements contained in this press release after the date hereof.

                          NEUROCRINE BIOSCIENCES, INC.
               CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                  (in thousands, except loss per share data)


                                        Three Months Ended   Nine Months Ended
                                           September 30,       September 30,
                                           -------------       -------------
                                           2009      2008      2009      2008
                                           ----      ----      ----      ----
                                            (unaudited)          (unaudited
'/>"/>
SOURCE Neurocrine Biosciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
2. Neurocrine Biosciences Presents Elagolix Data
3. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
6. Neurocrine Biosciences Reports First Quarter 2008 Results
7. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
8. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
9. Sangamo BioSciences Announces Plans to Initiate a Second Clinical Trial of CCR5-ZFP Therapeutic to Treat HIV/AIDS
10. Signum Biosciences Awarded Phase II SBIR Grant by the NIH for the Treatment of Rosacea
11. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... , 25. April 2015 Hospira, ... in der Entwicklung von Biosimilar-Behandlungen, sprach heute auf ... Europäischen Generikaverbands (EGA) in London ... mit der Verfügbarkeit von Biosimilars für Patienten. ... maßgeblichen White Papers mit dem Titel „Why ...
(Date:4/25/2015)... , April 25, 2015  With the introduction ... of precision cranial radiosurgery are now available for more ... sizes. This latest generation stereotactic radiosurgery system for the ... technologies, significantly increasing the versatility of Gamma Knife radiosurgery. ... 3 rd ESTRO Forum in Barcelona ...
(Date:4/24/2015)... , und BARCELONA ... (Stand Nr. 4410) iCAD, Inc. (Nasdaq: ... moderner Bildanalyse, Lösungen für Behandlungsabläufe und Strahlentherapie ... hat heute die sofortige Verfügbarkeit des ersten ... Brachytherapy (eBx ® ) System ® ...
Breaking Medicine Technology:Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 2Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 3Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 4Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 5Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 6Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 7Führungskräfte von Hospira präsentieren auf bedeutendem europäischen Biosimilars-Forum - Ankündigung eines White Papers über Extrapolation 8New Leksell Gamma Knife to benefit more patients with brain disease 2New Leksell Gamma Knife to benefit more patients with brain disease 3Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 2Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 3Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 4Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 5Erste Klinik in Spanien setzt das Xoft Electronic Brachytherapy System für die Behandlung von Brustkrebs im Frühstadium, nicht-melanozytärem Hautkrebs und gynäkologischen Krebserkrankungen ein 6
... 23, 2007 -,Gentium S.p.A. (NASDAQ: GENT) (the ... will be the subject of a poster,presentation ... being held in,Rio de Janeiro, Brazil from ... 2007, Cinara Echart, Ph.D., Manager of,Biological Research ...
... 24, 2007 /PRNewswire/ -- Accera Inc.,announced today that topline ... AC-1202 in Alzheimer's disease (AD) will be presented,at the ... in,Boston. Judged by the AAN to be in the ... be featured in the Scientific,Highlights Plenary Session. , Accera's ...
Cached Medicine Technology:Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 2Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology 3Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting 2
(Date:4/25/2015)... (PRWEB) April 26, 2015 The ... (ACE.S) , a national endeavor to prepare nurses to ... is a great success, according to a new report ... program's original funding partners. , The project began ... Philadelphia (CCP), under the direction of Elaine Tagliareni, EdD, ...
(Date:4/25/2015)... D.C. (PRWEB) April 25, 2015 In ... worldwide will join The Million Nets Pledge, a two-year ... campaign to protect refugee families with one million bednets ... their increased work with UN partners to protect children, ... from malaria. , “There has been a large ...
(Date:4/25/2015)... New York (PRWEB) April 25, 2015 ... established for vaginal mesh lawsuits filed against C.R. ... U.S. District Court, Southern District of West Virginia. ... a Scheduling Conference was convened that day, after ... Master Long Form Complaint. The Order directed that ...
(Date:4/25/2015)... The impact of the Trivedi Master Wellness™ ... the public and is likely to cause further, more ... June. From March 21st to March 31st, 2015, ... Prayers." More than 600 people participated in the program, ... have reported intense experiences that they attest have transformed ...
(Date:4/25/2015)... Phoenix, AZ (PRWEB) April 25, 2015 Parker ... plumbing, heating, and cooling, has spiked in Arizona alongside the ... on an additional forty employees for April to help account ... , “Hiring forty employees in April is something we are ... the economy,” said Paul Kelly, president at Parker and Sons. ...
Breaking Medicine News(10 mins):Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3Health News:Parker and Sons Plans to Expand in 2015 2
... addition to the Company,s line of health and ... April 23 AdEx Media, Inc. (OTC Bulletin ... and marketing platform services company, today announced the ... and beauty product strategic partnerships. RezActiv(TM) was ...
... outlook of $65.0 to $69.0 million- Case shipments of 50.1 ... GAAP diluted EPS of $0.04, compared to outlook of ($0.04) ... ALGN ) today reported financial results for the ... net revenues for the first quarter of fiscal 2009 (Q1 ...
... knowledge of CT-related radiation exposure and its associated risks, ... in Roanoke, VA. , "More than 100 surveys ... CT scans at a tertiary-care teaching hospital," said Jeremy ... knowledge regarding radiation was assessed, 63% underestimated the radiation ...
... OKLAHOMA CITY, April 23 Last night, Oklahoma Governor ... making it illegal for any Oklahoma business to conduct ... an unborn child to a substantial risk of death ... overrode the veto; however, the Oklahoma Senate failed to ...
... the market,s leading Security as a Service providers, was ... for "Best Managed Security Service" for the fourth year ... exclusive, SC Magazine Awards Gala, held in conjunction with ... Services competed against those from MessageLabs (now part of ...
... VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today ... lead oncology therapeutic Onrigin(TM) (laromustine) Injection has received a ... Administration (FDA). Therefore, a user fee goal date of ... with respect to the approval of the Company,s NDA ...
Cached Medicine News:Health News:AdEx Media Introduces RezActiv(TM) 2Health News:AdEx Media Introduces RezActiv(TM) 3Health News:Align Technology Announces First Quarter Fiscal 2009 Results 2Health News:Align Technology Announces First Quarter Fiscal 2009 Results 3Health News:Align Technology Announces First Quarter Fiscal 2009 Results 4Health News:Align Technology Announces First Quarter Fiscal 2009 Results 5Health News:Align Technology Announces First Quarter Fiscal 2009 Results 6Health News:Align Technology Announces First Quarter Fiscal 2009 Results 7Health News:Align Technology Announces First Quarter Fiscal 2009 Results 8Health News:Align Technology Announces First Quarter Fiscal 2009 Results 9Health News:Align Technology Announces First Quarter Fiscal 2009 Results 10Health News:Align Technology Announces First Quarter Fiscal 2009 Results 11Health News:Align Technology Announces First Quarter Fiscal 2009 Results 12Health News:Align Technology Announces First Quarter Fiscal 2009 Results 13Health News:Majority of ordering physicians lack knowledge of radiation exposure risks from CT 2Health News:SecureWorks, Inc. Wins SC Magazine's Reader Trust Award for Best Managed Security Service for Four Years Running 2Health News:Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM) 2Health News:Vion Pharmaceuticals Receives a Standard Review from the FDA for Its New Drug Application for Onrigin(TM) 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: